United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Invests $10.29 Million in Boston Scientific Corporation $BSX

Key Points

• United Super Pty Ltd disclosed a new fourth-quarter position in Boston Scientific, buying 107,888 shares valued at about $10.29 million. Other institutional investors also added to BSX, and hedge funds now own 89.07% of the company.
• Boston Scientific shares were down 2.7%, with the stock opening at $49.12 and trading near its 52-week low of $48.41. Despite the pullback, the company reported Q1 earnings and revenue slightly above expectations and issued guidance for continued growth in 2026.
• The company’s board authorized a $5 billion share repurchase program, signaling confidence in the stock’s valuation. Recent news was mixed, including positive clinical updates and insider buying, but also analyst downgrades tied to slower WATCHMAN procedures and competitive pressure in electrophysiology.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 107,888 shares of the medical equipment provider's stock, valued at approximately $10,287,000.

A number of other hedge funds also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. increased its holdings in Boston Scientific by 9.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 735,852 shares of the medical equipment provider's stock valued at $70,164,000 after purchasing an additional 63,773 shares during the period. Moors & Cabot Inc. increased its holdings in Boston Scientific by 3.0% during the 4th quarter. Moors & Cabot Inc. now owns 26,467 shares of the medical equipment provider's stock valued at $2,524,000 after purchasing an additional 780 shares during the period. Foundations Investment Advisors LLC increased its holdings in Boston Scientific by 4.5% during the 4th quarter. Foundations Investment Advisors LLC now owns 5,192 shares of the medical equipment provider's stock valued at $495,000 after purchasing an additional 225 shares during the period. Baker Avenue Asset Management LP increased its holdings in Boston Scientific by 4.5% during the 4th quarter. Baker Avenue Asset Management LP now owns 27,821 shares of the medical equipment provider's stock valued at $2,653,000 after purchasing an additional 1,190 shares during the period. Finally, Godfrey Financial Associates Inc. purchased a new position in Boston Scientific during the 4th quarter valued at about $322,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 2.7%

BSX stock opened at $49.12 on Friday. Boston Scientific Corporation has a fifty-two week low of $48.41 and a fifty-two week high of $109.50. The business's 50 day moving average price is $60.69 and its two-hundred day moving average price is $78.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a market capitalization of $73.01 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the business earned $0.75 EPS. The business's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the company's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the company's stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America reduced their price target on Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, May 18th. Daiwa Securities Group downgraded Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Wall Street Zen downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Truist Financial reduced their target price on Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a report on Thursday, April 23rd. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $109.00 to $71.00 and set a "buy" rating on the stock in a report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $87.46.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.